{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:45:11Z","timestamp":1791373511829,"version":"4.3.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI08504"],"award-info":[{"award-number":["AI08504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["FDN148386"],"award-info":[{"award-number":["FDN148386"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["706230"],"award-info":[{"award-number":["706230"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41590-022-01262-7","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:03:09Z","timestamp":1657814589000},"page":"1273-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-6234","authenticated-orcid":false,"given":"Giselle M.","family":"Boukhaled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Gadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Elsaesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"Abd-Rabbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Y. Cindy","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Noamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally C. M.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Saibil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-4754","authenticated-orcid":false,"given":"Naoto","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-2612","authenticated-orcid":false,"given":"Cynthia","family":"Guidos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"McGaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-7057","authenticated-orcid":false,"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-8764","authenticated-orcid":false,"given":"David G.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"1262_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","volume":"16","author":"GM Boukhaled","year":"2021","unstructured":"Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu Rev. Pathol. 16, 167\u2013198 (2021).","journal-title":"Annu Rev. Pathol."},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"e1005356","DOI":"10.1371\/journal.ppat.1005356","volume":"12","author":"CR Cunningham","year":"2016","unstructured":"Cunningham, C. R. et al. Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog. 12, e1005356 (2016).","journal-title":"PLoS Pathog."},{"key":"1262_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1172\/JCI89488","volume":"127","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Targeting type I interferon\u2013mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127, 260\u2013268 (2017).","journal-title":"J. Clin. Invest."},{"key":"1262_CR4","doi-asserted-by":"crossref","unstructured":"Sumida, T.S. et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 23, 632\u2013642 (2022).","DOI":"10.1038\/s41590-022-01152-y"},{"key":"1262_CR5","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1172\/JCI127458","volume":"129","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J. Clin. Invest. 129, 4224\u20134238 (2019).","journal-title":"J. Clin. Invest."},{"key":"1262_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","volume":"38","author":"LM Snell","year":"2017","unstructured":"Snell, L. M., McGaha, T. L. & Brooks, D. G. Type I interferon in chronic virus infection and cancer. Trends Immunol. 38, 542\u2013557 (2017).","journal-title":"Trends Immunol."},{"key":"1262_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1235208","volume":"340","author":"EB Wilson","year":"2013","unstructured":"Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202\u2013207 (2013).","journal-title":"Science"},{"key":"1262_CR8","doi-asserted-by":"publisher","unstructured":"Gadalla, R. et al. Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00415 (2019).","DOI":"10.3389\/fonc.2019.00415"},{"key":"1262_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-019-0541-0","volume":"7","author":"DL Clouthier","year":"2019","unstructured":"Clouthier, D. L. et al. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J. Immunother. Cancer 7, 72 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1262_CR10","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1262_CR11","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1262_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25432-7","volume":"12","author":"SY Cindy Yang","year":"2021","unstructured":"Cindy Yang, S. Y. et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat. Commun. 12, 5137 (2021).","journal-title":"Nat. Commun."},{"key":"1262_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41592-021-01282-5","volume":"18","author":"T Stuart","year":"2021","unstructured":"Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. & Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333\u20131341 (2021).","journal-title":"Nat. Methods"},{"key":"1262_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15543-y","volume":"11","author":"E Cano-Gamez","year":"2020","unstructured":"Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T cells to cytokines. Nat. Commun. 11, 1801 (2020).","journal-title":"Nat. Commun."},{"key":"1262_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nmeth.2810","volume":"11","author":"B Wang","year":"2014","unstructured":"Wang, B. et al. Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods 11, 333\u2013337 (2014).","journal-title":"Nat. Methods"},{"key":"1262_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41590-021-01060-7","volume":"22","author":"LM Snell","year":"2021","unstructured":"Snell, L. M. et al. Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nat. Immunol. 22, 1524\u20131537 (2021).","journal-title":"Nat. Immunol."},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.immuni.2018.04.026","volume":"48","author":"B Bengsch","year":"2018","unstructured":"Bengsch, B. et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity 48, 1029\u20131045.e1025 (2018).","journal-title":"Immunity"},{"key":"1262_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.4049\/jimmunol.1103246","volume":"188","author":"MA Kroenke","year":"2012","unstructured":"Kroenke, M. A. et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J. Immunol. 188, 3734\u20133744 (2012).","journal-title":"J. Immunol."},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"13324","DOI":"10.1073\/pnas.1507312112","volume":"112","author":"JP Nance","year":"2015","unstructured":"Nance, J. P. et al. Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3. Proc. Natl Acad. Sci. USA 112, 13324\u201313329 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1073\/pnas.1805239115","volume":"115","author":"E Shen","year":"2018","unstructured":"Shen, E. et al. Chromatin remodeling by the NuRD complex regulates development of follicular helper and regulatory T cells. Proc. Natl Acad. Sci. USA 115, 6780\u20136785 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1262_CR22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262\u20131280.e1222 (2021).","journal-title":"Cell"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"21510","DOI":"10.1074\/jbc.M212764200","volume":"278","author":"C Munz","year":"2003","unstructured":"Munz, C. et al. TAF7 (TAFII55) plays a role in the transcription activation by c-Jun. J. Biol. Chem. 278, 21510\u201321516 (2003).","journal-title":"J. Biol. Chem."},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"1262_CR25","doi-asserted-by":"crossref","unstructured":"Shakiba, M. et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J. Exp. Med. 219, e20201966 (2021).","DOI":"10.1084\/jem.20201966"},{"key":"1262_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1084\/jem.20101773","volume":"208","author":"LM Fahey","year":"2011","unstructured":"Fahey, L. M. et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208, 987\u2013999 (2011).","journal-title":"J. Exp. Med."},{"key":"1262_CR27","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.cell.2015.11.045","volume":"163","author":"AG York","year":"2015","unstructured":"York, A. G. et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 163, 1716\u20131729 (2015).","journal-title":"Cell"},{"key":"1262_CR28","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561\u20131577.e1567 (2021).","journal-title":"Immunity"},{"key":"1262_CR29","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F., Jaccard, A., Romero, P., Yu, Y.-R. & Ho, P.-C. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2, 1001\u20131012 (2020).","journal-title":"Nat. Metab."},{"key":"1262_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684 (2007).","journal-title":"Immunity"},{"key":"1262_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","volume":"22","author":"MS Abdel-Hakeem","year":"2021","unstructured":"Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat. Immunol. 22, 1008\u20131019 (2021).","journal-title":"Nat. Immunol."},{"key":"1262_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-021-00979-1","volume":"22","author":"KB Yates","year":"2021","unstructured":"Yates, K. B. et al. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat. Immunol. 22, 1020\u20131029 (2021).","journal-title":"Nat. Immunol."},{"key":"1262_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.20892\/j.issn.2095-3941.2020.0338","volume":"17","author":"Z Zeng","year":"2020","unstructured":"Zeng, Z., Wei, F. & Ren, X. Exhausted T cells and epigenetic status. Cancer Biol. Med. 17, 923\u2013936 (2020).","journal-title":"Cancer Biol. Med."},{"key":"1262_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495\u2013501 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1262_CR35","doi-asserted-by":"crossref","unstructured":"Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 1\u20138 (2022).","DOI":"10.1038\/s41586-022-04494-7"},{"key":"1262_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3389\/fimmu.2013.00291","volume":"4","author":"D Feng","year":"2013","unstructured":"Feng, D. & Barnes, B. J. Bioinformatics analysis of the factors controlling type I IFN gene expression in autoimmune disease and virus-induced immunity. Front. Immunol. 4, 291 (2013).","journal-title":"Front. Immunol."},{"key":"1262_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.immuni.2009.08.021","volume":"31","author":"M Sekimata","year":"2009","unstructured":"Sekimata, M. et al. CCCTC-binding factor and the transcription factor T-bet orchestrate T helper 1 cell-specific structure and function at the interferon-gamma locus. Immunity 31, 551\u2013564 (2009).","journal-title":"Immunity"},{"key":"1262_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","volume":"31","author":"H Shin","year":"2009","unstructured":"Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8+ T cell exhaustion during chronic viral infection. Immunity 31, 309\u2013320 (2009).","journal-title":"Immunity"},{"key":"1262_CR39","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1038\/ncomms7072","volume":"6","author":"C Zhu","year":"2015","unstructured":"Zhu, C. et al. An IL-27\/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat. Commun. 6, 6072\u20136072 (2015).","journal-title":"Nat. Commun."},{"key":"1262_CR40","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","volume":"338","author":"MA Paley","year":"2012","unstructured":"Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220\u20131225 (2012).","journal-title":"Science"},{"key":"1262_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442\u2013454 (2020).","journal-title":"Nat. Immunol."},{"key":"1262_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","volume":"26","author":"BP Fairfax","year":"2020","unstructured":"Fairfax, B. P. et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat. Med. 26, 193\u2013199 (2020).","journal-title":"Nat. Med."},{"key":"1262_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502.e415 (2017).","journal-title":"Cell"},{"key":"1262_CR44","doi-asserted-by":"crossref","unstructured":"Miron, M. et al. Human lymph nodes maintain TCF-1hi memory T cells with high functional potential and clonal diversity throughout life. J. Immunol. 201, 2132\u20132140 (2018).","DOI":"10.4049\/jimmunol.1800716"},{"key":"1262_CR45","doi-asserted-by":"publisher","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","volume":"1","author":"T Wu","year":"2016","unstructured":"Wu, T. et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).","journal-title":"Sci. Immunol."},{"key":"1262_CR46","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016\u201315021 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1262_CR47","doi-asserted-by":"publisher","first-page":"eabg8402","DOI":"10.1126\/scitranslmed.abg8402","volume":"14","author":"K Odunsi","year":"2022","unstructured":"Odunsi, K. et al. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci. Transl. Med. 14, eabg8402 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1262_CR48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"1262_CR49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389\u2013401 (2016).","journal-title":"Immunity"},{"key":"1262_CR50","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","volume":"81","author":"H Loo Yau","year":"2021","unstructured":"Loo Yau, H. et al. DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. Mol. Cell 81, 1469\u20131483.e1468 (2021).","journal-title":"Mol. Cell"},{"key":"1262_CR51","doi-asserted-by":"publisher","first-page":"a026948","DOI":"10.1101\/cshperspect.a026948","volume":"7","author":"T Sato","year":"2017","unstructured":"Sato, T., Issa, J.-P. J. & Kropf, P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb. Perspect. Med. 7, a026948 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1262_CR52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s40425-019-0799-2","volume":"7","author":"AB Nixon","year":"2019","unstructured":"Nixon, A. B. et al. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J. Immunother. Cancer 7, 325 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1262_CR53","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"1262_CR54","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"1262_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"1262_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"1262_CR57","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382\u20132383 (2015).","journal-title":"Bioinformatics"},{"key":"1262_CR58","first-page":"D87","volume":"48","author":"O Fornes","year":"2019","unstructured":"Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48, D87\u2013D92 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1262_CR59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nmeth.4401","volume":"14","author":"AN Schep","year":"2017","unstructured":"Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975\u2013978 (2017).","journal-title":"Nat. Methods"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-022-01262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-022-01262-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-022-01262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T16:03:37Z","timestamp":1659715417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-022-01262-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1038\/s41590-022-01262-7","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.H. provides consultation\/advice for Merck, GlaxoSmithKline, Bristol-Myers Squibb and Eisai, and receives research funding for Karyopharm Therapeutics, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Roche\/Genentech, Boeringher Ingelheim, Janssen, AstraZeneca\/MedImmune, Astellas and Macrogenics. A.S. is a consultant for (Advisory Board): Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated) and Janssen (compensated). A.S. receives grant\/research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca\/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology\/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma\/Pfizer, GSK, Treadwell. P.S.O. is a scientific advisory board member for Providence, Tessa and holds a sponsored research agreement with EMD Serono. M.O.B. is a consultant and on the advisory board for: Merck, Bristol-Myers Quibb, Novartis, GlaxoSmithKline, Sanofi, LaRoche, Possey, Sun Pharma, Instil Bio, IOVANCE and Pfizer, and receives grant funding from Merck, Takara and the safety review committee for Adaptimmune. G.M.B., H.J.E. and D.G.B. have filed a provisional patent pertaining to this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}